About: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment
Creator	Tsuji, Moriya Carvalho, Juliana Melgaço Garcez, Emãnuella Saldanha-Araujo, Felipe Amandda, Evelin Balkan, Wayne De Andrés, Belén Silva-Carvalho,
Source	Medline; PMC
abstract	COVID-19 is a disease characterized by a strong inflammatory response in severe cases, which fails to respond to corticosteroid therapy. In the context of the current COVID-19 outbreak and the critical information gaps regarding the disease, several different therapeutic strategies are under investigation, including the use of stem cells. In the present manuscript, we provide an analysis of the rationale underlying the application of stem cells to manage COVID-19, and also a comprehensive compendium of the 69 clinical trials underway worldwide aiming to investigate the application of stem cells to treat COVID-19. Even though data are still scarce, it is already possible to observe the protagonism of China in testing mesenchymal stem cells (MSCs) for COVID-19. Furthermore, it is possible to determine that current efforts focus on the use of multiple infusions of high numbers of stem cells and derived products, as well as to acknowledge the positive results obtained by independent groups who publicized the therapeutic benefits provided by such therapies in 51 COVID-19 patients. In such a rapid-paced field, up-to-date systematic studies and meta-analysis will aid the scientific community to separate hype from hope and offer an unbiased position to the society and governments.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.01563
bibo:pmid	32719683
has license	cc-by
sha1sum (hex)	9be326a1348383631d4c74d873be64540d21af95
schema:url	https://doi.org/10.3389/fimmu.2020.01563
resource representing a document's title	Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment
has PubMed Central identifier	PMC7347794
has PubMed identifier	32719683
schema:publication	Front Immunol
resource representing a document's body	covid:9be326a1348383631d4c74d873be64540d21af95#body_text
is schema:about of	named entity 'infecting humans' named entity 'Wuhan' named entity 'inflammatory factors' named entity 'ARDS' named entity 'critically ill' named entity 'COVID' named entity 'mammals' named entity 'Coronaviruses' named entity 'acute respiratory distress syndrome' named entity 'COVID-19 pandemic' named entity 'Janus kinase' named entity 'scientific papers' named entity 'trophic factors' named entity 'COVID' named entity 'COVID-19' named entity 'lung' named entity 'inflammatory diseases' named entity 'Egypt' named entity 'Tregs' named entity 'edema' named entity 'bone marrow' named entity 'intravenous' named entity 'anti-inflammatory' named entity '19, 20' named entity 'immunization' named entity 'World Health Organization' named entity 'ACE-2' named entity 'virus' named entity 'mesenchymal stem cell' named entity 'stem cells' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' named entity 'immune cells' named entity 'influenza virus' named entity 'COVID' named entity 'World Health Organization' named entity 'stem cell' named entity 'meta-analysis' named entity 'clinical studies' named entity 'ACE-2' named entity 'China' named entity 'immunomodulatory' named entity 'inflammatory disorders' named entity 'randomized trials' named entity 'advanced life support' named entity 'gold standard' named entity 'paracrine signaling' named entity 'adaptive immunity' named entity 'ClinicalTrials.gov' named entity 'stem cells' named entity 'clinical trials' named entity 'immunization' named entity 'hydroxychloroquine' named entity 'clinical studies' named entity 'mechanisms of action' named entity 'COVID-19' named entity 'Turkey' named entity 'double-blind' named entity 'lopinavir/ritonavir' named entity 'diarrhea' named entity 'adverse effects' named entity 'clinical studies' named entity 'inflammatory diseases' named entity 'endothelial cells' named entity 'viral diseases' named entity 'FDA' named entity 'dental pulp' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'public health' named entity 'abortive infection' named entity 'SARS-CoV-2 outbreak' named entity 'COVID' named entity 'stem cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software